Covid: Russian vaccine trials in UAE reach final phase

Abu Dhabi - 1,000 volunteers have successfully received the second dose of the vaccine.

Clinical trials of the Russian human adenovirus-based Covid-19 vaccine in the UAE have moved into the final monitoring phase, authorities in the country announced on Thursday.

Following the successful second dose vaccination of 1,000 volunteers, the next step involves monitoring volunteers’ immune response over a period of 180 days.

Findings of the UAE trials will be released by April and amalgamated with promising research findings from other global trials.

Recent interim results from Phase III of clinical trials of the Russian human adenovirus-based vaccine, as reported in leading international medical journal The Lancet, showed high efficacy of 91.6 per cent, as well as strong immunogenicity and safety results.

The UAE clinical trial is part of the Vaccine for Victory (V4V) campaign, the UAE’s chapter of the global vaccination trial of the Russian human adenovirus-based vaccine developed by Gamaleya National Research Institute of Epidemiology and Microbiology.

Dr Ahmed Al Hammadi, the trial’s principal investigator and Consultant Physician (Infectious Diseases) in the UAE, said, "Moving onto this next monitoring phase should be celebrated as an achievement for the UAE’s medical community. It’s an important precursor to studying the immune response in a diverse range of volunteers, paving the way for further securing the safety of our citizens and residents against Covid-19."